Výsledky vyhledávání - "HIV Integrase Inhibitors/administration"

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children Autor Turkova, Anna, White, Ellen, Mujuru, Hilda A, Kekitiinwa, Adeodata R, Kityo, Cissy M, Violari, Avy, Lugemwa, Abbas, Cressey, Tim R, Musoke, Philippa, Variava, Ebrahim, Cotton, Mark F, Archary, Moherndran, Puthanakit, Thanyawee, Behuhuma, Osee, Kobbe, Robin, Welch, Steven B, Bwakura-Dangarembizi, Mutsa, Amuge, Pauline, Kaudha, Elizabeth, Barlow-Mosha, Linda, Makumbi, Shafic, Ramsagar, Nastassja, Ngampiyaskul, Chaiwat, Musoro, Godfrey, Atwine, Lorna, Liberty, Afaaf, Musiime, Victor, Bbuye, Dickson, Ahimbisibwe, Grace M, Chalermpantmetagul, Suwalai, Ali, Shabinah, Sarfati, Tatiana, Wynne, Ben, Shakeshaft, Clare, Colbers, Angela, Klein, Nigel, Bernays, Sarah, Saïdi, Yacine, Coelho, Alexandra, Grossele, Tiziana, Compagnucci, Alexandra, Giaquinto, Carlo, Rojo, Pablo, Ford, Deborah, Gibb, Diana M

“…In an open-label, randomized, noninferiority trial, dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents…”
Získat plný text

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women Autor Landovitz, Raphael J, Donnell, Deborah, Clement, Meredith E, Hanscom, Brett, Cottle, Leslie, Coelho, Lara, Cabello, Robinson, Chariyalertsak, Suwat, Dunne, Eileen F, Frank, Ian, Gallardo-Cartagena, Jorge A, Gaur, Aditya H, Gonzales, Pedro, Tran, Ha V, Hinojosa, Juan C, Kallas, Esper G, Kelley, Colleen F, Losso, Marcelo H, Madruga, J. Valdez, Middelkoop, Keren, Phanuphak, Nittaya, Santos, Breno, Sued, Omar, Valencia Huamaní, Javier, Overton, Edgar T, Swaminathan, Shobha, del Rio, Carlos, Gulick, Roy M, Richardson, Paul, Sullivan, Philip, Piwowar-Manning, Estelle, Marzinke, Mark, Hendrix, Craig, Li, Maoji, Wang, Zhe, Marrazzo, Jeanne, Daar, Eric, Asmelash, Aida, Brown, Todd T, Anderson, Peter, Eshleman, Susan H, Bryan, Marcus, Blanchette, Cheryl, Lucas, Jonathan, Psaros, Christina, Safren, Steven, Sugarman, Jeremy, Scott, Hyman, Eron, Joseph J, Fields, Sheldon D, Sista, Nirupama D, Gomez-Feliciano, Kailazarid, Jennings, Andrea, Kofron, Ryan M, Holtz, Timothy H, Shin, Katherine, Rooney, James F, Smith, Kimberly Y, Spreen, William, Margolis, David, Rinehart, Alex, Adeyeye, Adeola, Cohen, Myron S, McCauley, Marybeth, Grinsztejn, Beatriz

“…Antiviral medication has emerged as an important tool in the prevention of HIV infection. In this randomized, controlled trial, an injectable long-acting…”
Získat plný text

Dolutegravir and weight gain: an unexpected bothering side effect? Autor Menard, Amélie, Meddeb, Line, Tissot-Dupont, Herve, Ravaux, Isabelle, Dhiver, Catherine, Mokhtari, Saadia, Tomei, Christelle, Brouqui, Philippe, Colson, Philippe, Stein, Andreas

Zjistit podrobnosti o přístupu

Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 Autor Marzinke, Mark A, Grinsztejn, Beatriz, Fogel, Jessica M, Piwowar-Manning, Estelle, Li, Maoji, Weng, Lei, McCauley, Marybeth, Cummings, Vanessa, Ahmed, Shahnaz, Haines, Casey D, Bushman, Lane R, Petropoulos, Christos, Persaud, Deborah, Adeyeye, Adeola, Kofron, Ryan, Rinehart, Alex, St Clair, Marty, Rooney, James F, Pryluka, Daniel, Coelho, Lara, Gaur, Aditya, Middelkoop, Keren, Phanuphak, Nittaya, Cohen, Myron S, Hendrix, Craig W, Anderson, Peter, Hanscom, Brett, Donnell, Deborah, Landovitz, Raphael J, Eshleman, Susan H

“…The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil…”
Zjistit podrobnosti o přístupu

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study Autor Cahn, Pedro, Pozniak, Anton L, Mingrone, Horacio, Shuldyakov, Andrey, Brites, Carlos, Andrade-Villanueva, Jaime F, Richmond, Gary, Buendia, Carlos Beltran, Fourie, Jan, Ramgopal, Moti, Hagins, Debbie, Felizarta, Franco, Madruga, Jose, Reuter, Tania, Newman, Tamara, Small, Catherine B, Lombaard, John, Grinsztejn, Beatriz, Dorey, David, Underwood, Mark, Griffith, Sandy, Min, Sherene

“…Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety,…”
Získat plný text

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir Autor Cottrell, Mackenzie L., Hadzic, Tanja, Kashuba, Angela D. M.

“…Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing…”
Získat plný text

HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety Autor Scarsi, Kimberly K., Havens, Joshua P., Podany, Anthony T., Avedissian, Sean N., Fletcher, Courtney V.

“…The newest class of antiretrovirals for all persons living with HIV are the integrase strand transfer inhibitors (INSTIs). Since 2007, five INSTIs have been…”
Získat plný text

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study Autor Raffi, Francois, Rachlis, Anita, Stellbrink, Hans-Jürgen, Hardy, W David, Torti, Carlo, Orkin, Chloe, Bloch, Mark, Podzamczer, Daniel, Pokrovsky, Vadim, Pulido, Federico, Almond, Steve, Margolis, David, Brennan, Clare, Min, Sherene

“…Dolutegravir (S/GSK1349572) is a once-daily HIV integrase inhibitor with potent antiviral activity and a favourable safety profile. We compared dolutegravir…”
Získat plný text

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial Autor Landovitz, Raphael J, Li, Sue, Eron, Jr, Joseph J, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Eshleman, Susan H, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Cohen, Myron S, McCauley, Marybeth, Hendrix, Craig W

“…Long-acting injectable cabotegravir is a novel integrase inhibitor currently in advanced clinical development for HIV prevention and treatment. We aimed to…”
Zjistit podrobnosti o přístupu

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial Autor Raffi, François, Jaeger, Hans, Quiros-Roldan, Eugenia, Albrecht, Helmut, Belonosova, Elena, Gatell, Jose M, Baril, Jean-Guy, Domingo, Pere, Brennan, Clare, Almond, Steve, Min, Sherene

“…In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with…”
Získat plný text

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV Autor Mulligan, Nikki, Best, Brookie M, Wang, Jiajia, Capparelli, Edmund V, Stek, Alice, Barr, Emily, Buschur, Shelley L, Acosta, Edward P, Smith, Elizabeth, Chakhtoura, Nahida, Burchett, Sandra, Mirochnick, Mark

“…To evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery. Ongoing, nonrandomized,…”
Zjistit podrobnosti o přístupu

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase Autor Siedner, Mark J., Moorhouse, Michelle A., Simmons, Bryony, de Oliveira, Tulio, Lessells, Richard, Giandhari, Jennifer, Kemp, Stephen A., Chimukangara, Benjamin, Akpomiemie, Godspower, Serenata, Celicia M., Venter, Willem D. F., Hill, Andrew, Gupta, Ravindra K.

“…Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of second generation integrase inhibitors. We sequenced pretreatment…”
Získat plný text

Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis Autor Perez Navarro, Andrea, Nutt, Cameron T, Siedner, Mark J, McCluskey, Suzanne M, Hill, Andrew

“…Abstract Background The long-acting injectable regimen of cabotegravir plus rilpivirine (CAB/RPV) emerged as an alternative to oral standard-of-care integrase…”
Získat plný text

Tolerability of integrase inhibitors in a real-life setting Autor Peñafiel, Judit, de Lazzari, Elisa, Padilla, Mireia, Rojas, Jhon, Gonzalez-Cordon, Ana, Blanco, Jose L, Blanch, Jordi, Marcos, Maria A, Lonca, Montserrat, Martinez-Rebollar, Maria, Laguno, Montserrat, Tricas, Amparo, Rodriguez, Ana, Mallolas, Josep, Gatell, Jose M, Martinez, Esteban

“…Integrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data have suggested potential differences…”
Zjistit podrobnosti o přístupu

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study Autor Orkin, Chloe, Oka, Shinichi, Philibert, Patrick, Brinson, Cynthia, Bassa, Ayesha, Gusev, Denis, Degen, Olaf, García, Juan González, Morell, Enrique Bernal, Tan, Darrell H S, D'Amico, Ronald, Dorey, David, Griffith, Sandy, Thiagarajah, Shanker, St Clair, Marty, Van Solingen-Ristea, Rodica, Crauwels, Herta, Ford, Susan L, Patel, Parul, Chounta, Vasiliki, Vanveggel, Simon, Cutrell, Amy, Van Eygen, Veerle, Vandermeulen, Kati, Margolis, David A, Smith, Kimberly Y, Spreen, William R

“…There is a need for more convenient, less frequent treatment to help address challenges associated with daily oral HIV treatment in people living with HIV,…”
Zjistit podrobnosti o přístupu

A lesson in embracing uncertainty in early safety signals from the Tsepamo study Autor Brummel, Sean S, Swanson, Sonja, Caniglia, Ellen, Lockman, Shahin, Zash, Rebecca, Shapiro, Roger

“…We investigated how randomness may have contributed to the apparent decline in observed risk of neural tube defects (NTDs) following in-utero dolutegravir…”
Zjistit podrobnosti o přístupu

Creation of a long-acting nanoformulated dolutegravir Autor Sillman, Brady, Bade, Aditya N., Dash, Prasanta K., Bhargavan, Biju, Kocher, Ted, Mathews, Saumi, Su, Hang, Kanmogne, Georgette D., Poluektova, Larisa Y., Gorantla, Santhi, McMillan, JoEllyn, Gautam, Nagsen, Alnouti, Yazen, Edagwa, Benson, Gendelman, Howard E.

“…Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer…”
Získat plný text

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial Autor van Lunzen, Jan, Maggiolo, Franco, Arribas, José R, Rakhmanova, Aza, Yeni, Patrick, Young, Benjamin, Rockstroh, Jürgen K, Almond, Steve, Song, Ivy, Brothers, Cindy, Min, Sherene

“…Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an ongoing study…”
Získat plný text

CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine Autor Muccini, Camilla, Gianotti, Nicola, Lolatto, Riccardo, Nozza, Silvia, Diotallevi, Sara, Castagna, Antonella

“…Our study assessed the CD4+/CD8+ ratio in people with HIV (PWH) switching from a second-generation integrase inhibitor regimen to long-acting cabotegravir…”
Zjistit podrobnosti o přístupu

Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection Autor Summa, Vincenzo, Petrocchi, Alessia, Bonelli, Fabio, Crescenzi, Benedetta, Donghi, Monica, Ferrara, Marco, Fiore, Fabrizio, Gardelli, Cristina, Paz, Odalys Gonzalez, Hazuda, Daria J., Jones, Philip, Kinzel, Olaf, Laufer, Ralph, Monteagudo, Edith, Muraglia, Ester, Nizi, Emanuela, Orvieto, Federica, Pace, Paola, Pescatore, Giovanna, Scarpelli, Rita, Stillmock, Kara, Witmer, Marc V., Rowley, Michael

“…Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for…”
Zjistit podrobnosti o přístupu